KEYTRUDA Padcev MIBC Survival: New Era in Treat...

By HEOR Staff Writer

March 2, 2026

KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies